Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...

Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for...

Introducing The BC5 Project: New Initiative to Empower Women to Explore All Breast Cancer Treatment Options NEW YORK, Sept. 10, 2013 (GLOBE NEWSWIRE) -- In an effort to ensure that all women diagnosed with early stage breast cancer are well-informed about their treatment options, a new group called The BC5...